Sarcoidosis is a multisystem, chronic granulomatous disorder, commonly affecting young adults and frequently presenting with bilateral hilar lymphadenopathy, pulmonary infiltrates and skin or eye lesions.
1,2 Although of unknown aetiology, sarcoidosis has been postulated to result from either a T-cell-mediated immune response against an environmental trigger or to be an abnormal immunological host response to a common antigenic trigger. 3 Sarcoidosis has been associated with infections, inflammatory conditions, and/or drugs, but it has rarely been reported following haemopoietic stem cell transplantation (HSCT). 4, 5 We report two patients who developed liver sarcoidosis following a reduced intensity conditioned (RIC) allogeneic HSCT.
The first patient, a 45-year-old Caucasian female diagnosed with myelodysplastic syndrome (MDS)-refractory cytopenia with multilineage dysplasia, was heavily transfusion-dependent and non-responsive to growth factor therapy. She underwent an HLA-matched unrelated donor RIC HSCT with FBC conditioning (fludarabine, busulphan and alemtuzumab). She required four doses of donor lymphocytes for falling donor CD3 (T-cell) chimerism, with the first dose given 5 months after transplant. She achieved full donor chimerism and was in morphological remission 1 year after transplant. At this time, elevations in several indices of hepatobiliary injury were noted, with alkaline phosphatase (ALP) 168 IU/l (expected: 30-130), aspartate transaminase (AST) 247 IU/l (10-50), g-glutamyl transpeptidase (GGT) 604 IU/l (1-55), and bilirubin (TBIL) 10 mmol/l (3-20). Her only medications were penicillin V 250 mg twice daily orally and aciclovir 200 mg three times daily orally. Ultrasonography and computerised tomography (CT) of the liver were unremarkable, and no serologic evidence of hepatitis A, B and C virus, cytomegalovirus, or Epstein-Barr virus ('hepatotropic-virus') infection was found. Clinical-biochemistry findings worsened (GGT 1004 IU/l). She developed purple-brown, firm skin lesions on the limbs, upper back and right cheek. The liver edge was palpable 3 cm below the right costal margin. Liver biopsy showed non-caseating granulomatous hepatitis with moderate portal fibrosis (Figure 1a) , and skin biopsy showed similar non-caseating granulomata (Figure 1b) , without fungi or acid-fast organisms in either; neither tissue yielded any growth on either routine or fungal and mycobacterial culture. Serum angiotensin converting enzyme (ACE) concentrations were elevated (117 U/l; expected 8-52), and CT of the chest showed multiple nodules throughout both lungs with mediastinal lymph node enlargement. Sarcoidosis was diagnosed and the patient began 15 mg of prednisolone orally once daily. Clinical-biochemistry findings after 2 months of treatment were improved (ALP 130 IU/l, AST 62 IU/l, GGT 469 IU/l), with normalisation of serum ACE levels.
The second patient was a 51-year-old Caucasian male, who underwent a FBC-conditioning RIC HSCT from a HLA-matched unrelated donor for fibrotic MDS with complex cytogenetics. A year before his transplant, he developed a blistering skin rash diagnosed as porphyria cutanea tarda on biopsy, with quantitation of porphyrins in blood, urine and faeces. No serologic evidence of hepatotropic-virus infection was found. Immediate transplant recovery was uneventful. Elevated indices of hepatobiliary injury were found 20 months after transplant (ALP 200 IU/ l, AST 63 IU/l, GGT 273 IU/l). His only medications were penicillin V 250 mg twice daily orally and lansoprazole 30 mg once daily orally. Liver biopsy found non-caseating granulomata, with mild fibrosis of portal tracts and moderate siderosis of hepatocytes (Figure 1c ). Mycobacteria and fungi were not identified by microscopy or on culture. Serum ACE levels were elevated at 160 U/l. Sarcoidosis was diagnosed. CT and routine radiography of the chest revealed no lesions. After oral prednisolone (30 mg once daily) was begun, ACE values normalised to 50 U/l. He is currently maintained on 5 mg of prednisolone once daily.
Hepatic impairment with elevation of hepatic transaminases is frequent after HSCT. The cause is often multi-factorial. Usual precipitants include graft-versus-host disease, drugs, veno-occlusive disease, sepsis and iron overload. 6 In contrast, it is rare to encounter sarcoidosis of the liver after HSCT. 5 We know of only four previous cases of patients developing sarcoidosis following allogeneic stem cell transplantation, 5,7-9 and of only one with hepatic sarcoidosis. 7 All previously reported patients received standard conditioning regimens, whereas both our patients underwent RIC-HSCT.
Sarcoidosis is an immune-mediated disorder, and the immune dysregulation and delayed immune reconstitution that follow HSCT may pre-dispose patients to develop sarcoidosis. All six patients known to date developed sarcoidosis after complete donor engraftment of their bone marrow, suggesting that the development of sarcoidosis in these circumstances was initiated by the donor immune system. Of interest is that three of the four previously reported patients received stem cells from siblings diagnosed with sarcoidosis. 5, 7, 8 However, in our patients neither of the donors had any evidence of sarcoidosis, and it is possible that the immune dysregulation following alemtuzumab-based conditioning 10 may have precipitated the development of sarcoidosis.
Our experience illustrates that the diagnosis of sarcoidosis can be delayed, as clinical-biochemistry evidence of hepatobiliary injury after HSCT is often attributed to infection or graft-versus-host disease. Sarcoidosis should be more frequently considered, and liver biopsy undertaken to permit definitive diagnosis, in this clinical setting. 
